Hardman Johnston Global Advisors released its Q3 2025 investor letter, reporting a 5.02% return for its global equity strategy portfolio, underperforming the MSCI AC World Net Index which returned 7.62%. Boston Scientific Corporation (NYSE:BSX) was highlighted as a key stock, with a one-month return of -4.78% and a market capitalization of $142.51 billion.

In the investor letter, Hardman Johnston Global Equity Strategy discussed Boston Scientific Corporation (NYSE:BSX) as a key driver of underperformance in the healthcare sector due to macro uncertainties such as the Trump administration’s Section 232 tariff investigation. Despite challenges, the company is viewed favorably with diversified growth prospects and new long-term targets for revenue growth, margin expansion, and EPS growth through 2028.

Boston Scientific Corporation (NYSE:BSX) reported consolidated revenue of $5.065 billion in Q3 2025, marking a 20.3% growth from the previous year. While the company showed potential as an investment, some AI stocks were considered to offer greater upside potential with lower downside risk. Hedge fund portfolios holding BSX increased to 102 in Q3 2025, indicating sustained interest in the company.

For more insights on Boston Scientific Corporation (NYSE:BSX) and other investor perspectives, visit Insider Monkey’s articles on the company and hedge fund investor letters for Q3 2025. Check out the best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that could double your money for further investment opportunities.

Read more at Yahoo Finance: A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook